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Abstract
Kainic acid (KA) binds to the AMPA/KA receptors and induces seizures that result in inflammation, oxidative damage and
neuronal death. We previously showed that cyclooxygenase-2 deficient (COX-2
2/2) mice are more vulnerable to KA-induced
excitotoxicity. Here, we investigated whether the increased susceptibility of COX-2
2/2 mice to KA is associated with altered
mRNA expression and editing of glutamate receptors. The expression of AMPA GluR2, GluR3 and KA GluR6 was increased in
vehicle-injected COX-2
2/2 mice compared to wild type (WT) mice in hippocampus and cortex, whereas gene expression of
NMDA receptors was decreased. KA treatment decreased the expression of AMPA, KA and NMDA receptors in the
hippocampus, with a significant effect in COX-2
2/2 mice. Furthermore, we analyzed RNA editing levels and found that the
level of GluR3 R/G editing site was selectively increased in the hippocampus and decreased in the cortex in COX-2
2/2
compared with WT mice. After KA, GluR4 R/G editing site, flip form, was increased in the hippocampus of COX-2
2/2 mice.
Treatment of WT mice with the COX-2 inhibitor celecoxib for two weeks decreased the expression of AMPA/KA and NMDAR
subunits after KA, as observed in COX-2
2/2 mice. After KA exposure, COX-2
2/2 mice showed increased mRNA expression of
markers of inflammation and oxidative stress, such as cytokines (TNF-a, IL-1b and IL-6), inducible nitric oxide synthase
(iNOS), microglia (CD11b) and astrocyte (GFAP). Thus, COX-2 gene deletion can exacerbate the inflammatory response to
KA. We suggest that COX-2 plays a role in attenuating glutamate excitotoxicity by modulating RNA editing of AMPA/KA and
mRNA expression of all ionotropic glutamate receptor subunits and, in turn, neuronal excitability. These changes may
contribute to the increased vulnerability of COX-2
2/2 mice to KA. The overstimulation of glutamate receptors as a
consequence of COX-2 gene deletion suggests a functional coupling between COX-2 and the glutamatergic system.
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Introduction
Cyclooxygenases (COX-1 and COX-2) convert arachidonic
acid to bioactive prostaglandins (PG) and tromboxanes (TX),
which have been implicated in important physiological functions
[1,2], as well as in the pathophysiology of several neurological and
neurodegenerative diseases, such as stroke, epilepsy, and Alzhei-
mer’s disease [3]. Although COX-2 is typically inducible, in the
central nervous system (CNS) both COX-1 and COX-2 are
constitutively expressed and COX-2 is mainly detected in the
perinuclear, dendritic and axonal domains of neurons, particularly
in cortex, hippocampus, amygdala and dorsal horn of the spinal
cord [4,5].
We have previously demonstrated that COX-2 deficient (COX-
2
2/2), but not COX-1
2/2 mice, are more susceptible to kainic-
acid (KA)-induced seizure intensity and neuronal damage [6]. KA,
the prototypic excitoxin, binds to the alpha-amino-propionic-acid/
kainate (AMPA/KA) and N-methyl-D-aspartic acid (NMDA)
receptors (AMPAR, KAR and NMDAR), which are subtypes of
the ionotropic glutamate receptors (iGluRs) in the brain [7],
inducing seizures that result in inflammation, oxidative damage
and neuronal death. These processes have been implicated in
neurological, neurodegenerative, and psychiatric diseases [6,8,9,
10,11,12,13,14,15].
Activation of AMPA/KA and NMDA receptors elicits a
number of cellular events, including the increase in intracellular
Ca
2+, production of ROS, and other biochemical events leading to
neuronal cell death [16,17,18,19,20]. In recent years, neurode-
generation caused by systemic injection of KA has been widely
used to investigate mechanisms of excitotoxicity mediated by
excitatory neurotransmitter agonists and possible pharmacological
neuroprotective interventions [6,21].
AMPA/KA and NMDA glutamate receptors play a major role
in excitatory synaptic transmission and plasticity. Their channel
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tetrameric receptor, assembled from GluR1–4 AMPA, GluR5–6
KA1 and KA2, NR1 with NR2a–d or NR3a–b, receptor subunits.
Molecular diversity of AMPA/KA and NMDA receptors under
physiological or pathological conditions is generated by differential
spatial-temporal patterns of GluR expression, by alternative RNA
splicing and editing and by targeting and trafficking of receptor
subunits at dendritic spines [22]. In particular, RNA editing is an
important post-transcriptional event in gene modification that
alters one or more translation codons, thereby giving rise to
functionally distinct proteins from a single gene [23]. The editing
positions have been named on the basis of amino acid substitution,
such as the Q/R site in AMPA GluR2 and KA GluR5 and GluR6
[23], the R/G site in GluR2, GluR3 and GluR4 [24] and the I/V
and Y/C site in GluR6 [25]. These amino acid changes lead to
modification of the channel properties: Q/R site profoundly
influences the ionic properties of AMPA and KA receptor [26,27]
and it may determine the maturation and cellular trafficking of
GluR2 [28,29], whereas the R/G site influences the kinetic aspect
of channel gating [24,30]. The GluR6 I/V and Y/C editing sites
may be involved, together with the Q/R site, in a finer regulation
of ion permeability [25]. Unlike GluR2 Q/R site, which is always
fully edited, the editing levels of the other sites are developmentally
[31] and regionally regulated [32,33].
It is well known that excess release of excitatory neurotransmit-
ters, such as glutamate and KA, is an important underlying cause of
neuronal damage in cerebral ischemia, epilepsy, Parkinson’s
disease, and Alzheimer’s disease [34,35,36]. This type of excita-
tion-induced neuronal damage is frequently accompanied by excess
calcium influx and followed by generation of reactive oxygen and
nitrogen species, which cause damage to intracellular membranes
and trigger apoptotic pathways leading to delayed cell death [21].
The aim of this study was to investigate mRNA editing
regulation of AMPA/KA receptor subunits and mRNA expression
of all ionotropic glutamate receptor subunits (AMPA/KA and
NMDA) in the cortex and hippocampus of COX-2
2/2 and wild
type (WT, COX-2
+/+) mice after KA exposure, and to determine
whether altered editing or expression of these receptors underlies
the increased susceptibility of COX-2
2/2 mice to KA-induced
seizure intensity and neuronal damage. Furthermore, we showed
that pretreatment with celecoxib for 2 weeks recapitulated the
effects on gene expression of some AMPA, KA and most of the
NMDA receptor subunits observed in COX-2
2/2 mice, after KA
treatment.
We also investigated the neuroinflammatory response of
COX-2
2/2 and WT mice to systemic KA injection by measuring
the expression of inflammatory markers in the brain. We
demonstrate that COX-2
2/2 mice show an increase in the gene
expression of microglia (CD11b) and astrocyte (GFAP) markers,
pro-inflammatory cytokines (TNF-a, IL-1b and IL-6), and
inducible nitric oxide syntase (iNOS).
Materials and Methods
Ethics Statement
All animal experiments were performed under an animal
protocol (NICHD #08-026) approved by the National Institutes of
Health (NIH), National Institute of Child Health and Disease
(NICHD) Animal Care and Use Committee, in accordance with
the NIH guidelines on the care and use of laboratory animals.
Animal housing
Six week-old male COX-2
2/2 and WT mice on a C57Bl/6-
129/Ola background were received from a private NIEHS colony
maintained by Taconic Farms (Germantown, NY) separately from
their commercially available colony [37,38]. All mice used in this
study were progeny derived from heterozygous by heterozygous
matings and therefore all contained the same strain and genetic
background. Mice were maintained on a 12 h light/dark cycle
with free access to food and water intake. For celecoxib
pretreatment, WT mice were given free access for two weeks to
a diet containing 6000 ppm celecoxib. Celecoxib (Celebrex
TM)
capsules (400 mg; Pfizer Inc., New York, NY) were obtained from
the NIH Division of Veterinary Medicine and were incorporated
into feed by Research Diets, Inc. (New Brunswick, NJ) [6].
Kainate injection
KA injection was performed as previously described [6]. Briefly,
12–14-week-old male mice were injected intraperitoneally (i.p.)
with 10 mg/kg KA (Biomol International, Plymouth Meeting, PA;
2 mg/ml in 0.9% saline) or vehicle (0.9% saline). This dose of KA
caused seizures but did not result in fatalities in WT mice [6]. Mice
were euthanized after 24 h after KA injection and brains used for
molecular analysis were rapidly dissected, frozen in 2-methylbu-
tane at 250uC, and stored at 280uC until use.
Gene expression
Fresh frozen mouse hippocampus and cerebral cortex were
processed for RNA extraction using the Qiagen RNeasy Lipid
Tissue Mini kit (Qiagen, Valencia, CA), as directed by the
manufacturer. RNA quantification and quality control were done
using both spectrophotometric analysis and the AGILENT
Bioanalyzer 2100 lab-on-a-chip technologies. Retro-Transcription
(RT) was done using the Moloney murine leukemia virus-reverse
transcriptase (MMLV-RT) (Invitrogen). 2.5 mg of total RNA were
mixed with 2.2 ml of 0.2 ng/ml random hexamer (Invitrogen),
10 mlo f5 6 buffer (Invitrogen), 10 ml of 2 mM dNTPs, 1 mlo f
1 mM DTT (Invitrogen), 0.4 mlo f3 3U / ml RNasin (Promega),
2 ml MMLV-RT (200 U/ml), in a final volume of 50 ml. The
reaction mix was incubated at 37uC for 2 h and then the enzyme
heat inactivated at 95u for 10 min. To perform the PCR reactions
different amount of the RT product were mixed with 2.5 ml1 0 6
buffer (Polymed), 0.7 ml of 1.5 mM MgCl2, 2.5 ml of 2 mM dNTP,
0.7 ml of each forward and reverse primer, 1.25 U of Taq
polymerase in a final volume of 25 ml [39].
Quantitative real-time polymerase chain reaction (RT-PCR) was
performed on selected genes AMPA GluR1–4 (Applied Biosystems
TaqMan Gene Expression Assay id probes: GluR1 Mm00433-
753_m1; GluR2 Mm00442822_m1; GluR3 Mm00497506_m1;
GluR4 Mm00444754_m1); KA GluR5–7, KA1 and KA2 (GluR5
Mm00446882_m1; GluR6 Mm00599860_m1; GluR7 Mm01179-
716_m1; KA1 Mm00615472_m1; KA2 Mm00433774_m1);
NMDA NR1, NR2a–d and NR3a–b (NR1 Mm00433800_m1;
NR2a Mm00433802_m1; NR2b Mm00433820_m1; NR2c Mm0-
0439180_m1;NR2d Mm00433822_m1;NR3a Mm01341723_m1;
NR3b Mm00504568_m1); cytokine (TNFa: Mm00443258_m1;
IL-1b: Mm00434228_m1; IL-6: Mm01210733_m1); glial fibrillary
acid protein (GFAP: Mm01253033_m1); microglial marker
(CD11b: Mm00434455_m1); transcription factor (NF-kB: Mm-
00501346_m1); microtubule associate protein 2 (Mtap2: Mm00-
485230_m1); Nitric oxide species (iNOS: Mm00440485_m1) and
phosphoglicerate kinase 1 (pgk1: Mm01225301_m1) as reference
genes. PCR reactions were performed using the Applied Biosystems
7500 system. Data were analyzed using the comparative threshold
cycle (DD Ct) method [40]. Results were normalized with Pgk1 as
the endogenous control, and expressed as fold difference from the
vehicle-injected WT mice, as previously reported [41,42].
Glutamate Receptors Editing
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19398Quantification of editing levels
The editing level quantification for AMPA GluR2, GluR3 and
GluR4 and KA GluR5 and GluR6 transcripts was done by RT-
PCR and sequence analysis [33]. Briefly, following amplification of
the region containing the editing site, a pool of GluR cDNA was
obtained in which both the edited and unedited mRNA forms
were co-expressed. The PCR products were sequenced and the
edited nucleotide appeared as overlapping A/G peaks: A from
unedited transcripts and G from the edited ones [33]. The
percentage of edited mRNA molecules in a pool of specific GluR
mRNAs can be determined by calculating the peak area of the
edited nucleotide (G) versus the sum of G and A peak areas using
the software DS gene that permit to analyze the area of the peak.
We previously determined that the editing level can be reliably
calculated as a function of the ratio between the G peak area and
A plus G peaks areas [33]. The nucleotide areas were quantified
by the Discovery Studio Gene 1.5 program (Accelrys Inc., San
Diego, CA, USA) [43]. The mean values and standard errors from
each group of animals were used for statistical analysis.
Statistical analysis
Editing and expression data were obtained by amplifying the
mRNA from each animal. The mean values and standard errors
obtained from each group were reported. Editing data were
analyzed with Student’s t-test. For RT- PCR results, a two-way
ANOVA was performed on the log-transformed DD Ct.
Bonferroni’s post-hoc test was used for further comparisons. p
values,0.05 were considered statistically significant. Data ob-
tained in celecoxib-treated animals were analyzed using a one-way
ANOVA, followed by a Bonferroni’s post-hoc test.
Results
mRNA expression of AMPA and KA glutamate receptor
subunits is decreased in COX-2
2/2 mice after KA
injection
Using qRT-PCR, we examined the relative changes in the
mRNA expression pattern of the AMPA (GluR1–4) and KA
(GluR5–7, KA1 and KA2) glutamate receptors subunits in the
hippocampus and cortex of vehicle-injected COX-2
2/2 mice
(n=9) compared with vehicle-injected WT mice (n=9). Further-
more, we analyzed the expression levels of the receptor subunits of
KA-injected WT (n=9) and COX-2
2/2 mice (n=9) compared
with their respective controls. Also we analyzed the mRNA
expression of KA-injected COX-2
2/2 mice compared with KA-
injected WT mice.
In the hippocampus (Fig. 1A–I) of vehicle-injected COX-2
2/2
mice the mRNA expression of GluR2, GluR3 and GluR6 was
significantly increased (GluR2: 1.2260.06, p,0.001; GluR3:
1.2660.04, p,0.001; GluR6: 1.3960.05, p,0.001), as compared
with vehicle-injected WT mice (Fig. 1B, C; Fig. 1F). These data
indicate that COX-2 deletion alters the transcription rate of
glutamate receptor genes.
KA injection affected the expression pattern of several AMPA
and KA receptor subunits both in WT and COX-2
2/2 mice.
Specifically, the mRNA expression of all GluR subunits (except
GluR6) from KA-injected WT mice showed a decrease of about
20–50% when compared with vehicle-injected WT mice (Mean 6
SEM; GluR1: 0.7560.04, p,0.001; GluR2: 0.7660.04, p,0.001;
GluR3: 0.7960.04, p,0.001; GluR4: 0.7860.05, p,0.01;
GluR5: 0.8060.02, p,0.001; GluR7: 0.6860.04, p,0.001;
KA1: 0.5060.02, p,0.001; KA2: 0.7360.03, p,0.001)
(Fig. 1A–I).
Furthermore, KA-injected COX-2
2/2 mice showed a signifi-
cant decrease in the mRNA expression of all AMPA and KA
subunits (except GluR7 and KA1) (GluR1: 0.6260.04, p,0.001:
GluR2: 0.5660.02, p,0.001; GluR3: 0.5760.02, p,0.001;
GluR4: 0.6660.03, p,0.01; GluR5: 0.6760.07, p,0.05; GluR6:
0.7560.02, p,0.001; KA2: 0.860.06, p,0.01), as compared with
vehicle-injected COX-2
2/2 mice (Fig. 1A–I). Small but significant
changes of about 20–30% were observed for the GluR1, GluR5
and KA2 subunits (GluR1: 0.8260.06, p,0.01: GluR5:
0.7260.05, p,0.001; KA2: 0.8060.04, p,0.05) between KA-
injected COX-2
2/2 mice and KA-injected WT mice (Fig. 1A,
1E–1I).
In the cortex, similarly to the changes observed in the
hippocampus, we found an increase in the expression of GluR2,
GluR3, GluR6 and GluR7 (GluR2: 1.4260.09, p,0.001; GluR3:
1.2860.02, p,0.001; GluR6: 1.4460.10, p,0.001; GluR7:
1.4060.06, p,0.001) in vehicle-injected COX-2
2/2 mice com-
pared with WT mice (Fig. 2B–C, 2F–G).
Furthermore, the mRNA expression of GluR3 and KA1
subunits was decreased in KA-injected WT mice compared to
vehicle-injected WT mice (GluR3: 0.7860.05, p,0.001; KA1:
0.7260.03, p,0.01) (Fig. 2C, 2I). Moreover, a down-regulation in
the mRNA expression of AMPA GluR2–3 and KA GluR6–7 was
observed in KA-injected COX-2
2/2 mice compared with vehicle-
injected COX-2
2/2 mice (GluR2: 0.7860.02, p,0.001; GluR3:
0.8960.04, p,0.05; GluR6: 0.7460.02, p,0.05; GluR7:
0.8760.02, p,0.05) (Fig. 2B–C, 2F, 2H).
mRNA expression of NMDA glutamate receptor subunits
is decreased in COX-2
2/2 mice after KA injection
Next, we examined the relative changes in the mRNA
expression pattern of the NMDA (NR1, NR2a–d and NR3a–b)
glutamate receptors subunits in the hippocampus and cortex of
vehicle-injected COX-2
2/2 mice (n=9) compared with vehicle-
injected WT mice (n=9). Then, we analyzed the expression levels
of the same receptor subunits of KA-injected WT (n=9) and COX-
2
2/2 mice (n=9) compared with their respectively controls. Also
we analyzed the mRNA expression of KA-injected COX-2
2/2
mice compared with KA-injected WT mice.
In the hippocampus of vehicle-injected COX-2
2/2 mice the
mRNA expression of all NMDA receptor subunits, except for
NR2b, was significantly decreased as compared with vehicle-
injected WT mice (NR1: 0.6260.02, p,0.001; NR2a: 0.4860.01,
p,0.001; NR2c: 0.5760.02, p,0.001; NR2d: 0.6060.02,
p,0.001; NR3a: 0.6760.01, p,0.001; NR3b: 0.4660.12,
p,0.05) (Fig. 3A–G). Furthermore, the mRNA expression of all
NMDA subunits (except NR2b) from KA-injected WT mice were
decreased when compared with vehicle-injected WT mice (NR1:
0.5960.04, p,0.001; NR2a: 0.5560.05, p,0.001; NR2c:
0.5560.04, p,0.001; NR2d: 0.5660.04, p,0.001; NR3a:
0.6860.03, p,0.001; NR3b: 0.5060.09, p,0.05) (Fig. 3A–G).
Also, KA-injected COX-2
2/2 mice showed a significant decrease
in the mRNA expression of all NR subunits, except NR1, NR2a
and NR3a, as compared with vehicle-injected COX-2
2/2 mice
(NR2b: 0.7160.02, p,0.001: NR2c: 0.4860.1, p,0.001; NR2d:
0.5960.07, p,0.01; NR3a: 0.6160.05, p,0.001) (Fig. 3A–G). A
decrease of about 30–50% was observed in the expression of all
NR subunits, except NR1 and NR3b, between KA-injected COX-
2
2/2 and KA-injected WT mice (NR2a: 0.6360.03, p,0.01;
NR2b: 0.7060.02, p,0.001; NR2c: 0.4960.14, p,0.001; NR2d:
0.6060.07, p,0.01; NR3a: 0.6060.05, p,0.001) (Fig. 3A–G).
In the cortex, the expression of NR1, NR2a, NR2c and NR2d
subunits was decreased when we compared vehicle-injected
COX-2
2/2 (NR1: 0.7260.06, p,0.001; NR2a: 0.6760.02,
Glutamate Receptors Editing
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19398Figure 1. KA-induced mRNA expression of AMPA/KA receptor subunits in the hippocampus of COX-2
+/+ and COX-2
2/2 mice.
Quantitative real time-PCR analysis of GluR1 (A), GluR2 (B), GluR3 (C), GluR4 (D) GluR5 (E), GluR6 (F), GluR7 (G), KA1 (H), KA2 (I) for COX-2
+/+ and COX-2
2/2
mice 24 h after i.p. injection of KA or vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and Bonferroni’s
post-hoc test to compare replicate means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05, ##P,0.01,
###P,0.001, compared to vehicle-injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2 and KA-injected
WT mice.
doi:10.1371/journal.pone.0019398.g001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19398Figure 2. KA-induced expression of AMPA/KA receptor subunits in the cortex of COX-2
+/+ and COX-2
2/2 mice. Quantitative real time-
PCR analysis of GluR1 (A), GluR2 (B), GluR3 (C), GluR4 (D), GluR5 (E), GluR6 (F), GluR7 (G), KA1 (H), KA2 (I) for COX-2
+/+ and COX-2
2/2 mice 24 h after i.p.
injection of KA or vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and Bonferroni’s post-hoc test to
compare replicate means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05, ##P,0.01, ###P,0.001,
compared to vehicle-injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2 and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19398Figure 3. KA-induced expression of NMDA receptor subunits in the hippocampus of COX-2
+/+ and COX-2
2/2 mice. Quantitative real
time-PCR analysis of NR1 (A), NR2a (B), NR2b (C), NR2c (D), NR2d (E) NR3a (F), NR3b (G) for COX-2
+/+ and COX-2
2/2 mice 24 h after i.p. injection of KA or
vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and Bonferroni’s post-hoc test to compare replicate
means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05, ##P,0.01, ###P,0.001, compared to vehicle-
injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2 and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g003
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p,0.05) with vehicle-injected WT mice (Fig. 4A–G). An increase
of about 40% was observed in the expression of the NR2b subunit
in vehicle-injected COX-2
2/2 compared with vehicle-injected
WT mice (NR2b: 1.4260.09, p,0.001). Also, the expression of
NR1, NR2a, NR2c and NR2d subunits was decreased when we
compared KA-injected WT with vehicle-injected WT mice (NR1:
0.7360.04, p,0.01; NR2a: 0.7160.02, p,0.001; NR2c:
0.8060.06, p,0.01) (Fig. 4A–G).
A down-regulation in the expression of several NR subunits
(NR2b: 0.7460.05, p,0.05; NR2c: 0.7060.05, p,0.01; NR2d:
0.7360.04, p,0.05; NR3b: 0. 5060.10, p,0.05) was observed in
KA-injected COX-2
2/2 mice compared with vehicle-injected
COX-2
2/2 mice (Fig. 4A–G). A significant decrease of about 30–
50% was observed in the expression of NR2a, NR2c and NR2d
subunits between KA-injected COX-2
2/2 mice and KA-injected
WT mice (NR2a: 0.6360.03, p,0.01; NR2c: 0.7060.02,
p,0.001; NR2d: 0.4960.14, p,0.001) (Fig. 4A–G).
Pretreatment with celecoxib altered mRNA expression of
AMPA/KA and NMDA glutamate receptor subunits in WT
mice after KA injection
We examined the relative changes in the mRNA expression of
the AMPA (GluR1–4), KA (GluR5–7, KA1 and KA2) and
NMDA (NR1, NR2a–d, NR3a–b) glutamate receptor subunits in
the hippocampus and cortex of mice treated for two weeks with
celecoxib, a COX-2 selective inhibitor, prior to KA injection, in
vehicle-injected and KA-injected WT mice (n=9).
In the hippocampus, no changes were observed when we
compared vehicle-injected and celecoxib treated mice (data not
shown). KA injection affected the expression of all AMPAR, KAR
(except GluR6) and NMDAR subunits in both celecoxib untreated
controls (GluR1: 0.7860.02, p,0.001; GluR2: 0.7660.03,
p,0.001; GluR3: 0.7960.04, p,0.01; GluR4: 0.7860.05,
p,0.001; GluR5: 0.8060.02, p,0.001; GluR7: 0.6860.04,
p,0.05; KA1: 0.5060.02, p,0.001; KA2: 0.7360.03, p,0.001;
NR1: 0.5960.05, p,0.001; NR2a: 0.5560.02, p,0.001; NR2c:
0.5560.05, p,0.001; NR2d: 0.5660.04, p,0.001; NR3a:
0.6860.03, p,0.001; NR3b: 0.5060.09, p,0.001) and cele-
coxib-treated WT mice (GluR1: 0.3860.02, p,0.001; GluR2:
0.3260.01, p,0.001; GluR3: 0.2760.01, p,0.001; GluR4:
0.5760.02, p,0.001; GluR5: 0.6060.02, p,0.001; GluR7:
0.5060.02, p,0.001; KA1: 0.5060.01, p,0.001; KA2:
0.3560.01, p,0.001; NR1: 0.3760.01, p,0.001; NR2a:
0.2460.003, p,0.001; NR2b: 0.2760.01, p,0.001; NR2c:
0.3860.02, p,0.001; NR2d: 0.3960.02, p,0.001; NR3a:
0.1860.01, p,0.001; NR3b: 0.2060.03, p,0.001) when com-
pared with vehicle-injected WT mice (Fig. 5A–I and Fig. 6A–G).
Celecoxib pretreatment significantly decreased the mRNA
expression of most iGluRs in KA-injected mice (GluR1:
0.5060.02, p,0.001; GluR2: 0.4160.01, p,0.001; GluR3:
0.3460.01, p,0.001; GluR4: 0.7360.02, p,0.01; GluR5:
0.7660.02, p,0.001; GluR6: 0.8860.02, p,0.01; KA2:
0.4860.01, p,0.001; NR1: 0.6260.02, p,0.05; NR2a:
0.4360.01, p,0.001; NR2b: 0.3060.01, p,0.001; NR3a:
0.2760.02, p,0.001; NR3b: 0.4160.05, p,0.01) (Fig. 5A–I
and Fig. 6A–G).
In the cortex, no changes were observed when we compared
vehicle-injected and celecoxib treated mice (data not shown). KA
injection affected the expression of several AMPAR, KAR and
NMDAR subunits in both celecoxib-untreated (GluR3:
0.7860.05, p,0.001; KA1: 0.7060.03, p,0.001; KA2:
0.8060.03, p,0.001; NR1: 0.7060.03, p,0.001; NR2a:
0.7460.01, p,0.001; NR2b: 0.8460.04, p,0.05; NR2c:
0.7560.06, p,0.01; NR2d: 0.8360.05, p,0.05) and celecoxib-
pretreated mice (GluR4: 0.6160.02, p,0.001; GluR5:
0.8660.03, p,0.05; GluR7: 0.7260.06, p,0.05; KA1:
0.6660.01, p,0.001; KA2: 0.6560.03, p,0.001; NR1:
0.4560.03, p,0.001; NR2a: 0.4760.06, p,0.001; NR2b:
0.6160.03, p,0.001; NR2c: 0.2960.01, p,0.001; NR2d:
0.3760.01, p,0.001; NR3b: 0.4960.12, p,0.05) when com-
pared with vehicle-injected WT mice (Fig. 7A–I and Fig.
8A–G).
Although the effect was less robust than the one observed in the
hippocampus, after KA injection celecoxib-pretreated mice
showed reduced cortical mRNA expression of several iGluRs
compared with celecoxib-untreated mice (GluR4: 0.6760.03,
p,0.001; GluR7: 0.6960.06, p,0.05; KA2: 0.8160.03, p,0.01;
NR1: 0.6460.04, p,0.001; NR2a: 0.6360.08, p,0.01; NR2b:
0.7360.04, p,0.01; NR2c: 0.3860.001, p,0.001; NR2d:
0.4260.02, p,0.001). Celecoxib pretreatement increased the
expression of GluR3 (1.260.03, p,0.05) in response to KA
injection (Fig. 7A–I and Fig. 8A–G).
Pattern of in vivo mRNA editing levels of GluRs after KA
treatment
Since the function of AMPA glutamatergic receptors is
modulated by the mRNA editing of the different subunits, we
analyzed editing levels of GluR2 Q/R and R/G sites, GluR3 and
GluR4 R/G sites, GluR5 Q/R site and GluR6 I/V, Y/C and Q/
R sites in the hippocampus and cortex. The AMPA R/G sites
were analyzed in combination with the AMPA splicing variants
called flip and flop [24].
In all mice tested the editing level of GluR2 Q/R site was
virtually 100%, with no variations due to either KA injection or
genotype (data not shown). In hippocampus and cortex, no
changes were detected in the R/G site, flip- and flop-isoforms, of
GluR2 in either KA- injected WT mice or in vehicle-injected
COX-2
2/2 mice when compared with vehicle-injected WT mice
(Table S1, Supplementary data).
In the hippocampus, the GluR3 R/G site for the flip isoform
showed a small but significant increase after KA injection in WT
mice (8.4%, p,0.001) and vehicle-injected COX-2
2/2 mice
(8.4%, p,0.001) when compared to vehicle-injected WT mice
(Fig. 9A). In the cortex, we found a decrease (216.4%, p,0.001)
in the GluR3 R/G site for the flip variant in vehicle-injected
COX-2
2/2 mice when compared with vehicle-injected WT mice
(Fig. 10A).
Similarly, in the hippocampus, GluR4 R/G site, flip variant,
showed an increase after KA injection in both WT (8%, p,0.05)
and COX-2
2/2 mice (8%, p,0.05) when compared with vehicle-
injected WT mice (Fig. 9B). No changes were observed in the
editing levels of GluR3 (Fig. 9A and Fig. 10A) and GluR4 R/G
site (Fig. 9B and Table S1), flop-isoform, after KA injection or
between genotypes in the hippocampus or cortex.
No changes by genotype or KA-treatment were found in the
editing level of kainate GluR5 Q/R site in the hippocampus or in
the cortex (Table S1). GluR6 Y/C and Q/R sites were not altered
by KA treatment either in the hippocampus (Table S1) or cerebral
cortex (Fig. 10B). However, there was a small but statistically
significant increase in the I/V site in the cortex of KA-injected
WT mice (p,0.001) and vehicle-injected COX-2
2/2 mice
(p,0.001) when compared with vehicle-injected WT mice
(Fig. 10B). Furthermore, we analyzed editing levels of the different
subunits in mice pretreated for two weeks with celecoxib. No
changes due to KA-treatment or celecoxib were detected either in
the hippocampus or cortex (Table S2, Supplementary data).
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19398Figure 4. KA-induced mRNA expression of NMDA receptor subunits in the cortex of COX-2
+/+ and COX-2
2/2 mice. Quantitative real
time-PCR analysis of NR1 (A), NR2a (B), NR2b (C), NR2c (D), NR2d (E) NR3a (F), NR3b (G) for COX-2
+/+ and COX-2
2/2 mice 24 h after i.p. injection of KA or
vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and Bonferroni’s post-hoc test to compare replicate
means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05, ##P,0.01, ###P,0.001, compared to vehicle-
injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2 and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19398Figure 5. Effects of pretreatment with celecoxib on KA-induced expression of AMPA/KA receptor subunits in the hippocampus of
wild type mice. Quantitative real time-PCR analysis of GluR1 (A), GluR2 (B), GluR3 (C), GluR4 (D), GluR5 (E), GluR6 (F), GluR7 (G), KA1 (H), KA2 (I) in WT
mice, after two weeks treatment with celecoxib, followed by an i.p. injection of KA or vehicle 24 hours later. Data are means 6 SEM (n=9). Statistical
analysis was performed using a one-way ANOVA and Bonferroni’s post-hoc test. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected WT mice;
#P,0.05, ##P,0.01, ###P,0.001 compared to KA-injected WT mice ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2
and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g005
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19398Figure 6. Effects of pretreatment with celecoxib on KA-induced expression of AMPA/KA receptor subunits in the cortex of wild type
mice. Quantitative real time-PCR analysis of GluR1 (A), GluR2 (B), GluR3 (C), GluR4 (D) in WT mice, after two weeks treatment with celecoxib, followed
by an i.p. injection of KA or vehicle 24 hours later. Data are means 6 SEM (n=9). Statistical analysis was performed using a one-way ANOVA and
Bonferroni’s post-hoc test. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected WT mice; #P,0.05, ##P,0.01, ###P,0.001 compared to
KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g006
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PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19398Figure 7. Effects of pretreatment with celecoxib on KA-induced mRNA expression of NMDA receptor subunits in the hippocampus
of wild type mice. Quantitative real time-PCR analysis of NR1 (A), NR2a (B), NR2b (C), NR2c (D), NR2d (E) NR3a (F), NR3b (G) in WT mice, after two
weeks treatment with celecoxib, followed by an i.p. injection of KA or vehicle 24 hours later. Data are means 6 SEM (n=9). Statistical analysis was
performed using a one-way ANOVA and Bonferroni’s post-hoc test. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected WT mice; #P,0.05,
##P,0.01, ###P,0.001 compared to KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g007
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PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e19398Figure 8. Effects of pretreatment with celecoxib on KA-induced mRNA expression of NMDA receptor subunits in the hippocampus
of wild type mice. Quantitative real time-PCR analysis of NR1 (A), NR2a (B), NR2b (C), NR2c (D), NR2d (E) NR3a (F), NR3b (G) in WT mice, after two
weeks treatment with celecoxib, followed by an i.p. injection of KA or vehicle 24 hours later. Data are means 6 SEM (n=9). Statistical analysis was
performed using a one-way ANOVA and Bonferroni’s post-hoc test. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected WT mice; #P,0.05,
##P,0.01, ###P,0.001 compared to KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g008
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PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e19398mRNA expression of genes involved in the
neuroinflammatory response is increased in COX-2
2/2
mice after KA
Gene expression of cytokines was determined using real time
PCR in hippocampus and cortex. In the hippocampus, no changes
were observed in the mRNA expression of all inflammatory
markers analyzed when we compared vehicle-injected COX-2
2/2
with vehicle-injected WT mice (Fig. 11A–C). These data indicate
that COX-2 deletion per se does not alter the transcription rate of
inflammatory markers. KA-injection significantly increased the
expression of TNF-a, IL-1b and IL-6 in both COX-2
2/2 and WT
mice, however, the increase was significantly higher in the COX-
2
2/2 mice (P,0.001; Fig. 11A–C).
In the cortex, no changes was observed in the mRNA
expression of TNF-a, IL-1b and IL-6 genes when we compared
vehicle-injected COX-2
2/2 with vehicle-injected WT mice
(Fig. 12A–C). KA-injection increased the expression of TNF-a
(3.0560.41, p,0.001), IL-1b (1.4860.09, p,0.01) and IL-6 genes
(1.8360.39, p,0.01) in COX-2
2/2 mice and the expression of
TNF-a (1.8960.17, p,0.05) in WT mice (Fig. 12A–C). The
increase in the gene expression of TNF-a was significantly higher
in KA-injected COX-2
2/2 than in KA-injected WT mice
(1.6160.29, p,0.05; Fig. 12A).
To determine glial cell response, we examined the gene
expression of GFAP, a specific marker for astrocytes, and CD11b,
a specific marker for microglia. No changes were observed in either
brainareas analyzed inthe mRNA expression of GFAP and CD11b
when we compared vehicle-injected COX-2
2/2 with vehicle-
injected WT mice (Fig. 11E–F, Fig. 12E–F).
In the hippocampus, KA increased the expression of GFAP and
CD11b, with a more significant effect in COX-2
2/2 (GFAP:
3.8360.16, p,0.001; CD11b: 2.4660.20, p,0.01) than in WT
mice (GFAP: 2.1460.24, p,0.001; CD11b: 1.9160.19, p,0.01)
(Fig. 11E–F). Moreover, KA-injected COX-2
2/2 mice showed a
higher increase in the expression of GFAP (1.8860.13, p,0.01)
and CD11b (1.2660.11, p,0.05) when compared with KA-
injected WT mice (Fig. 11E–F). In the cortex, KA-injected COX-
2
2/2 showed an increase in the expression of GFAP (1.8960.17,
Figure 9. KA-induced editing of AMPA editing site glutamate receptor subunits in the hippocampus of COX-2
+/+ and COX-2
2/2
mice. Evaluation of RNA editing levels of the AMPA glutamate receptors in the hippocampus of mice injected with KA. (A) GluR3 R/G site flip- flop-
variant and (B) GluR4 R/G flip- flop-variant, editing site. Data are presented as mean 6 SEM (n=6). Statistical analysis was performed with Student’s t
test (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0019398.g009
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PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e19398p,0.05) when compared to vehicle-injected COX-2
2/2 mice. No
changes were observed in the mRNA expression of CD11b
(Fig. 12E–F).
No change was observed in the mRNA expression of iNOS, a
major source or oxidative stress, when we compared vehicle-
injected COX-2
2/2 with vehicle-injected WT mice in the
hippocampus or cortex (Fig. 11G, Fig. 12G). In the hippocampus,
COX-2
2/2 mice (2.1960.22, p,0.001) showed a higher increase
in iNOS mRNA levels in response to KA compared to WT mice
(1.6160.14, p,0.01). Also, KA-injected COX-2
2/2 mice showed
an increase in the expression of iNOS (1.3660.15, p,0.05) when
compared with KA-injected WT mice (Fig. 11G). In the cortex, no
changes were observed in the expression of iNOS in any of the
groups (Fig. 12G).
Furthermore, we analyzed the mRNA expression of the pro-
inflammatory transcription factor NF-kB. In the hippocampus, an
increase in the mRNA levels of NF-kB was observed in KA-
injected compared to vehicle-injected COX-2
2/2 mice
(1.2060.05, p,0.001) (Fig. 11D). KA-injected COX-2
2/2 mice
showed an increase in the expression of NF-kB (1.1960.06,
p,0.01) when compared with KA-injected WT mice (Fig. 11D).
In the cortex, no changes were observed in the expression of NF-
kB in any of the groups analyzed (Fig. 12G).
Next, we examined mRNA gene expression of MAP-2 that
belongs to the microtubule-associated protein family, which is
enriched in neuronal cell bodies and dendrites. In the hippocam-
pus, KA-injection significantly increased the expression of MAP-2
(1.4360.09, p,0.01) in COX-2
2/2 mice (Fig. 11H). In the
cortex, no change was observed in MAP-2 gene expression
(Fig. 12H). The mRNA expression of COX-1 was not significantly
changed in either COX-2
2/2 and WT mice after KA exposure in
either brain areas (data not shown), indicating that the increased
neuroinflammatory response was not due to an increased
compensatory expression of COX-1 in response to KA as a
consequence of COX-2 gene deletion.
Discussion
In this study, we report for the first time a complete analysis of
mRNA expression for all subunits of AMPA (GluR1–4), KA
(GluR5–7, KA1 and KA2) and NMDA (NR1, NR2a–b and
NR3a–b) receptors in the hippocampus and cortex from COX-
2
2/2 and WT mice after KA injection. We used KA as a model of
excitotoxicity because of its strong and well-characterized time and
regional effects in inducing seizures and subsequent neuronal
damage. Administration of KA has been shown to increase
Figure 10. KA-induced editing of AMPA and KA glutamate receptor subunits in the cortex of COX-2
+/+ and COX-2
2/2 mice. RNA
editing levels of AMPA and KA glutamate receptors in the cerebral cortex of mice exposed to acute KA-injection. (A) GluR3 R/G site flip- flop-variant
and (B) GluR6 I/V, Y/C and Q/R editing site. Data are presented as mean 6 SEM (n=6). Statistical analysis was performed with Student’s t test
(*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0019398.g010
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PLoS ONE | www.plosone.org 14 May 2011 | Volume 6 | Issue 5 | e19398Figure 11. KA-induced expression of genes involved in the neuroinflammatory response in the hippocampus of COX-2
+/+ and COX-
2
2/2 mice. Quantitative real time-PCR analysis of TNF-a (A), IL-1b (B), IL-6 (C), NF-kB (D), GFAP (E), CD11b (F), iNOS (G), MAP-2 (H) for COX-2
+/+ and
COX-2
2/2 mice 24 h after i.p. injection of KA or vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and
Bonferroni’s post-hoc test to compare replicate means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05,
##P,0.01, ###P,0.001, compared to vehicle-injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2
and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g011
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PLoS ONE | www.plosone.org 15 May 2011 | Volume 6 | Issue 5 | e19398Figure 12. KA-induced expression of genes involved in the neuroinflammatory response in the cortex of COX-2
+/+ and COX-2
2/2
mice. Quantitative real time-PCR analysis of TNF-a (A), IL-1b (B), IL-6 (C), NF-kB (D), GFAP (E), CD11b (F), iNOS (G), MAP-2 (H) for COX-2
+/+ and COX-2
2/2
mice 24 h after i.p. injection of KA or vehicle. Data are means 6 SEM (n=9). Statistical analysis was performed using a two-way ANOVA and
Bonferroni’s post-hoc test to compare replicate means. *P,0.05, **P,0.01, ***P,0.001 compared to vehicle-injected COX-2
+/+ mice; #P,0.05,
##P,0.01, ###P,0.001, compared to vehicle-injected COX-2
2/2 mice; ﬁP,0.05, ﬁﬁP,0.01, ﬁﬁﬁP,0.001 between KA-injected COX-2
2/2
and KA-injected WT mice.
doi:10.1371/journal.pone.0019398.g012
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PLoS ONE | www.plosone.org 16 May 2011 | Volume 6 | Issue 5 | e19398production of reactive oxygen species, mitochondrial dysfunction,
and apoptosis in neurons in many regions of the brain, particularly
in the hippocampal CA1 and CA3 subfields, and hilus of dentate
gyrus. KA also produces inflammatory responses typically found in
neurodegenerative diseases. Several studies suggest that KA-
induced excitotoxicity can be used as a model for elucidating
mechanisms underlying oxidative stress and inflammation in
neurodegenerative diseases [14,16,44].
Our data show that AMPA GluR2–3 and KA GluR6 mRNA
levels are up-regulated in the hippocampus of COX-2
2/2 mice
while the mRNA expression of all NMDA receptor subunits is
down-regulated. KA injection caused a general decrease in the
mRNA of AMPARs (GluR1–4), KARs (GluR5, GluR7, KA1–
KA2) and NMDARs (NR1, NR2a–d, NR3a) in the hippocampus
of both COX-2
+/+ mice and COX-2
2/2 mice, whereas in the
cortex only KA1, NR1, NR2a and NR2c mRNA levels were
decreased.
These data indicate that COX-2
2/2 mice might suffer of an
imbalance of glutamate receptor expression. We observed an
increase in the transcription levels for AMPA (GluR2 and GluR3)
and KA (GluR6) receptor subunits in both the hippocampus and
cortex of vehicle-injected COX-2
2/2 mice compared to WT
mice, whereas the mRNA levels of NMDA subunits were generally
decreased. The net effect of this action might be an increased
glutamatergic throughput of AMPARs relative to NMDA
receptors. Thus, we can speculate that genetic deletion of COX-
2 alters the functional interplay between AMPA and NMDA
receptors, leading to the dampening of NMDA receptors and
potentiation of AMPA receptors. These data confirm a role of
COX-2 in modulating the expression of glutamate receptors.
Moreover, the imbalance in glutamatergic neurotransmission
could contribute, at least in part, to the increased susceptibility
of COX-2
2/2 mice to KA-induced seizure intensity and neuronal
damage that we previously described [6].
The NMDA receptor is formed by NR1 subunits interacting
with NR2A–D, conferring functional variability depending on the
specific subunits involved [45]. NR2A and NR2B are the major
NR2 subunits in the adult neocortex and hippocampus. NR2A is
confined to synapses of mature neurons, whereas NR2B is
distributed mainly extrasynaptically [46]. Synaptic NMDA
receptor activity is extremely important for neuronal survival,
while the extrasynaptic NMDAR is coupled to cell-death pathways
[47].
Recently, a new mechanism of autoregulation of the NMDA
receptor induced by agonists overactivaction in mature neurons
has been described by Gascon and colleagues [48]. The decrease
in the expression of NMDAR subunits that we found in celecoxib-
treated and COX-2
2/2 mice after KA may be explained by this
mechanism of autoregulation in response to glutamate activation.
NMDAR overactivation may downregulate the function of
synaptic receptors in neurons in response to excitotoxic neuronal
degeneration. NR1 can also be regulated by a late-onset
mechanism consisting of transcriptional suppression of NR1
obligatory subunit under excitotoxic conditions [49]. Inhibition
of NR1 synthesis might also result in a progressive decrease in the
activity of synaptic and extrasynaptic NMDARs. Calcium influx
and brief stimulation of NMDARs with excitotoxic concentrations
of agonist is sufficient to irreversibly reduce the level of this
receptor subunit. These mechanisms of autoregulation of the
NMDARs may also be involved in KA-induced changes in the
expression of NMDARs and subsequent excitoxicity and neuronal
degeneration.
The increased susceptibility to KA-induced excitotoxicity of
COX-2
2/2 mice raises an important issue regarding the possible
involvement of COX-2 in neuroprotection and glutamatergic
neurotransmission [6]. Specifically, COX-2 could play a role in
attenuating glutamate excitotoxicity and, consequently, Ca
2+
influx, by indirectly modulating the transcription of AMPA/KA
and NMDA receptors.
After KA injection we observed a global down-regulation of
AMPA/KA and NMDA mRNA expression, in WT and to a
greater extent in COX-2
2/2 mice. Following its depolarizing
actions, KA may enhance intracellular accumulation of Ca
2+ to
promote selective neuronal damage. Neuronal cells might protect
themselves from the damaging overstimulation, inducing the
observed decrease in the overall glutamate receptors expression, in
an attempt to maintain homeostasis.
Our data agree with a previous report by Grooms et al (2000)
showing that KA administration caused delayed death of
pyramidal neurons in the hippocampal CA1 and CA3 subfields
that was preceded by down-regulation of GluR2 mRNA and
protein expression [50]. Thus, AMPA receptor subunits may play
an important role in the neurotoxicity induced by KA, although
the mechanism underlying the involvement of this class of
receptors in excitotoxicity should be further investigated. It is
believed that the behavioral and neuropathological changes
induced by KA are initiated by the activation of KA receptors
in the CA3 region of the hippocampus [10], followed by release of
the endogenous excitatory amino acids, glutamate, and aspartate
[11], with an activation of all types of glutamate receptors.
Ohno et al (1997) [51] showed that KA-induced excitotoxicity
in embryonic rat hippocampal cultures is mediated by AMPA but
not KA receptors, and involves NMDA receptor-mediated toxicity
through the response of KA mediated by AMPA-preferring
receptors. Non-NMDA receptor-mediated excitotoxicity has been
proposed to contribute to neuronal loss in a broad range of
pathological conditions including hypoxia, hypoglycemia, ische-
mia, epilepsy, trauma [52,53], amyotrophic lateral sclerosis [54],
Huntington’s disease [55], and Alzheimer’s disease [56,57].
Regulation of glutamate receptors subunits is complex and
includes several intracellular steps, from transcriptional to post-
translational modifications, which may have functional conse-
quences on receptor subunit rearrangement and lead to functional
differences in the functioning of synaptic circuits. Specifically,
several reports clearly indicate that changes in editing of specific
glutamate receptor subunits are accompanied by corresponding
changes in the physiological properties of the channels
[23,26,27,58]. Our data indicate that KA also modulated RNA
editing, a post-transcriptional mechanism known to alter func-
tional properties of selected subunits of AMPA and KA receptors
and to induce a fine-tuning modulation of glutamate neurotrans-
mission [23]. RNA editing reaction influences the structure and,
most importantly, the function of the receptor, by acting at
different levels: RNA editing modulates RNA splicing of several
glutamate receptors [24], and Q/R RNA editing modulates
receptor transport from the endoplasmic reticulum to the plasma
membrane and mediates GluR subunit tetramerization [28,29]. At
the functional level, Q/R RNA editing modulates ionic transport
through GluR receptor channels [26,27], whereas R/G RNA
editing modulates desensitization and the recovery time of GluR
receptors [30]. Thus, the physiological action of glutamate seems
to rely greatly on a proper RNA editing reaction. Supporting this
notion, recent reports show that changes in the editing level may
have a profound impact on glutamatergic neurotransmission in
epilepsy [59,60,61], amyotrophic lateral sclerosis (ALS) [62,63],
spinal cord injury [43] and malignant gliomas [64].
In our study, the GluR2 Q/R site, the most important editing
site for modulation of AMPA receptor channel properties,
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analyzed, indicating that modifications in calcium permeability of
AMPA receptors were not involved in KA action.
In the hippocampus, we observed an increase in GluR3 and
GluR4 R/G level after KA injection in both WT and COX-2
2/2
mice. Our data suggest that increased editing at the AMPA R/G
site, by altering resensitization kinetics, could enhance the receptor
response to glutamate, resulting in a synapse operating at an
increased gain. The potentially higher frequency of post-synaptic
receptor activation due to fast resensitization kinetics, might in this
case lead to an increased Ca
2+ concentration in the post-synaptic
neuron.
On the other hand, in the cortex, we found a decrease in the
GluR3 R/G site editing, flip form, in vehicle-injected COX-2
2/2
compared with WT mice. Although no changes in editing levels
were observed after KA injection, the observed decrease in GluR3
R/G site editing might cause a selective reduction of conductance
for GluR3-containing receptors after KA.
Regarding the editing levels of KA receptors, KA injection
selectively affected only the GluR6 I/V site in the cortex,
indicating that KA slightly decreased cation permeability of the
GluR6-containing receptor channels. The observed increase in I/
V GluR6 levels might indicate an excitotoxin-induced decrease in
the activity of voltage-gated glutamatergic channels of the KA
subtype. It is possible that desensitization at KA-preferring
receptors plays an important role in neuroprotection.
Furthermore, we showed that pretreatment with celecoxib for 2
weeks recapitulated the effects on gene expression of some AMPA,
KA and most of the NMDA receptor subunits observed in COX-
2
2/2 mice after KA exposure, suggesting that the effects observed
were not due to life-time compensatory changes that may exist in
knockout mice. No alteration in the editing reaction was observed
after celecoxib treatment, indicating that editing levels are
extremely conserved and editing modifications may occur only
after a longer treatment or in a situation of life-time inhibition of
COX-2 activity as observed in COX-2
2/2 mice.
Furthermore, we observed that COX-2 gene deletion enhanced
the neuroinflammatory response to KA. KA increased mRNA
expression of pro-inflammatory cytokines, such as TNF-a, IL-1b
and IL-6, iNOS, a marker of oxidative stress, GFAP, a marker for
astrocytes, and CD11b, a marker for microglia. These data are
consistent with previous reports from our and other groups
showing that COX-2 gene deletion or inhibition increases the
neuroinflammatory response to endotoxins [42]. iNOS may also
contribute to microglia-mediated KA induced neurotoxicity by
increasing the production of extracellular reactive oxygen and
nitrogen species, which, in turn, stimulate microglial release of
pro-inflammatory mediators that, like radical oxygen species, are
toxic to neurons.
MAP2 gene expression was increased in the hippocampus of
COX-2
2/2 mice after KA. MAP2 exhibits microtubule-stabilizing
activity and regulates the microtubule networks in dendrites,
resulting in dendrite elongation [65]. Thus, as reported in
surviving neurons of medial extended amygdala after status
epilepticus [66], KA might induce a process of sprouting and
reactive synaptogenesis.
In conclusion, we have previously shown that Cox-2
2/2 mice
are more susceptible to KA-induced seizures and neuronal
damage [6]. Although some of the changes observed in this model
may be the consequence of adaptive modifications due to deletion
of the COX-2 gene, chronic administration of the Cox-2 selective
inhibitor celecoxib recapitulated these findings [6]. While we
cannot directly link changes in glutamate receptor editing to
susceptibility to KA, we speculate that altered mRNA editing and
expression of glutamate receptors in COX-2
2/2 mice could cause
an imbalance in the interplay between AMPA and NMDA
receptors and alterations in glutamatergic neurotransmission.
These alterations might contribute, at least in part, to the
increased susceptibility of COX-22/2 mice to KA-induced
excitotoxicity [6]. Overall, our findings suggest a role of COX-2
in modulating the expression of glutamate receptors and, in turn,
regulating glutamatergic neurotransmission. Future studies are
warranted to elucidate the molecular mechanisms that underline
the interplay between COX-2 gene and the glutamatergic system.
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